Target Name: GATD3
NCBI ID: G8209
Review Report on GATD3 Target / Biomarker Content of Review Report on GATD3 Target / Biomarker
GATD3
Other Name(s): C21orf33 variant 1 | KNPH | GATD3A variant 3 | Chromosome 21 open reading frame 33, transcript variant 1 | GT335 | ES1 | Chromosome 21 open reading frame 33, transcript variant X | glutamine amidotransferase class 1 domain containing 3 | human HES1 protein, homolog to E.coli and zebrafish ES1 protein | ES1 protein homolog, mitochondrial (isoform X4) | ES1 protein homolog, mitochondrial precursor | C21orf33 variant 2 | Chromosome 21 open reading frame 33, transcript variant 2 | KNPI | C21orf33 variant X | Testis secretory sperm-binding protein Li 237E | glutamine amidotransferase class 1 domain containing 3A | glutamine amidotransferase-like class 1 domain-containing protein 3A, mitochondrial | C21orf33 | Glutamine amidotransferase like class 1 domain containing 3A, transcript variant 3 | HES1 | GATD3A | ES1 protein homolog, mitochondrial (isoform 2) | ES1 protein homolog, mitochondrial | Keio novel protein I | glutamine amidotransferase like class 1 domain containing 3A | Human HES1 protein, homolog to E.coli and zebrafish ES1 protein | Protein KNP-I | Glutamine amidotransferase class 1 domain containing 3, transcript variant 4 | testis secretory sperm-binding protein Li 237E | GATD3 variant 4 | Protein GT335 | ES1 protein homolog, mitochondrial precursor (isoform Ia) | Glutamine amidotransferase-like class 1 domain-containing protein 3A, mitochondrial (isoform 3)

Study on GATD3 (C21orf33 Variant 1): Potential Drug Target Or Biomarker

GATD3 (C21orf33 variant 1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic variation has led to the development of a unique expression profile, which has implications for its function and potential as a therapeutic target.

GATD3 is a gene that encodes for a protein known as GATD3, which is a key regulator of mitochondrial function and has been implicated in a number of cellular processes. The GATD3 gene has four splice variants, each of which has a unique exon and gene sequence .Among them, variant 1 (c.1385-1405) is the most abundant and has been extensively studied.

Variant 1 is a common variation that has been identified in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It has been shown to be involved in a number of cellular processes, including cell growth, differentiation, and apoptosis (programmed cell death).

One of the most significant features of GATD3 variant 1 is its unique expression profile. It has been shown to be expressed in a wide range of tissues and cells, including the brain, spinal cord, and heart. It is also expressed in various types of cancer, including lung, breast, and ovarian cancer.

In addition to its expression in cancer cells, GATD3 variant 1 has also been shown to be involved in the regulation of cellular processes that are important for maintaining brain health and function. It has been shown to play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

GATD3 variant 1 has also been shown to be involved in the regulation of immune responses, which is important for maintaining overall health and preventing disease. It has been shown to play a role in the development and regulation of autoimmune disorders, including rheumatoid arthritis, lupus , and multiple sclerosis.

In conclusion, GATD3 (C21orf33 variant 1) is a gene that has a unique expression profile and has been implicated in a number of cellular processes that are important for maintaining health and preventing disease. Its potential as a drug target or biomarker makes it an attractive target for further research and development. Further studies are needed to fully understand its function and potential as a therapeutic agent.

Protein Name: Glutamine Amidotransferase Class 1 Domain Containing 3

The "GATD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GATD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GATM | GATOR1 Complex | GAU1 | GBA1 | GBA2 | GBA3 | GBAP1 | GBE1 | GBF1 | GBGT1 | GBP1 | GBP1P1 | GBP2 | GBP3 | GBP4 | GBP5 | GBP6 | GBP7 | GBX1 | GBX2 | GC | GCA | GCAT | GCC1 | GCC2 | GCC2-AS1 | GCDH | GCFC2 | GCG | GCGR | GCH1 | GCHFR | GCK | GCKR | GCLC | GCLM | GCM1 | GCM2 | GCN1 | GCNA | GCNT1 | GCNT1P3 | GCNT2 | GCNT3 | GCNT4 | GCNT7 | GCOM1 | GCSAM | GCSAML | GCSAML-AS1 | GCSH | GCSHP3 | GCSIR | GDA | GDAP1 | GDAP1L1 | GDAP2 | GDE1 | GDF1 | GDF10 | GDF11 | GDF15 | GDF2 | GDF3 | GDF5 | GDF6 | GDF7 | GDF9 | GDI1 | GDI2 | GDI2P1 | GDNF | GDNF Family Receptor alpha | GDNF-AS1 | GDPD1 | GDPD2 | GDPD3 | GDPD4 | GDPD5 | GDPGP1 | GEM | GEMIN2 | GEMIN4 | GEMIN5 | GEMIN6 | GEMIN7 | GEMIN8 | GEMIN8P1 | GEMIN8P4 | GEN1 | general transcription factor IIF (TFIIF) | General transcription factor IIH | Geranylgeranyl transferase | Geranylgeranyl transferase type-1 | GET1 | GET3 | GET4 | GFAP | GFER | GFI1